Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Assess a biotech company with convertible debt by analyzing its development milestones, available cash, and debt contract together. The central questions are whether the company can fund its programs to meaningful milestones, what the notes require if financing or clinical progress falters, and how conversion could affect both cash needs and existing shareholders’ ownership. Start with the company’s latest filings and executed debt documents; a headline debt balance or a stated cash runway cannot answer those questions alone.
Why biotech development risk and convertible debt must be assessed together
Biotechnology companies can need substantial capital before clinical development, regulatory review, and commercialization generate revenue. Trial timing, study outcomes, manufacturing, and regulatory steps can all affect how much funding is needed and when. If more capital is unavailable, an issuer may have to delay, reduce, or terminate development. A company’s trial stage or announced plan is not evidence that a product will be approved or commercially successful.
Convertible debt adds a second set of uncertainties. Depending on the instrument, the company may owe scheduled payments or principal at maturity, may have to settle certain obligations in cash, or may issue shares on conversion. Conversion can reduce an immediate cash repayment burden while diluting existing holders; it does not by itself eliminate the company’s repayment risk.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Use issuer filings for current company-specific information, and read the contract to identify the actual obligations. In its Form 10-Q for the quarter ended June 30, 2026, Latigo Biotherapeutics, Inc. cautioned: “We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all.” That is the company’s disclosure about its financing risk, not a general forecast for every biotech issuer.
#1 Best Overall
How to assess the company’s development and funding needs
Map programs to milestones
For each material program, note its preclinical or clinical stage, the next planned milestones, expected trial timing and design, manufacturing dependencies, and regulatory steps. Then estimate what funding is needed before each milestone and what the company says it might do if a study is delayed, fails, or costs more than expected. Separate concrete commitments from plans and expectations.
Reconstruct runway from current financial statements
Start with the latest balance sheet and cash-flow statement. Distinguish unrestricted cash from restricted or otherwise unavailable balances. Review operating cash use alongside accrued expenses, debt service, committed trial costs, manufacturing commitments, and financings that have actually closed. Compare management’s runway estimate with the assumptions behind it and the costs of upcoming milestones.
Build at least two scenarios: a base case using the company’s stated timing and funding assumptions, and an adverse case in which a trial or financing is delayed. The point is not to produce a precise forecast from incomplete information; it is to identify whether a delay could leave the company unable to fund planned work or meet debt obligations. Recalculate when new filings, trial events, financing, or amendments change the inputs.
Which documents reveal the real terms of the debt?
Do not rely only on a balance-sheet label, press release, or summary of the financing. Read the executed note or indenture, relevant security agreement, amendments, and the latest filing’s debt footnote. Record the provisions that determine proceeds, payments, conversion, creditor rights, and the company’s options:
- Proceeds and repayment: face principal; cash actually received after any original issue discount and fees; coupon; one-time interest; payment-in-kind terms; amortization schedule; and maturity date.
- Conversion mechanics: whether conversion is automatic or optional; triggering events and dates; who controls the choice; and whether settlement is in cash, shares, or a combination.
- Conversion-price formula: discounts, valuation caps, floors, resets, lookback periods, beneficial-ownership limits, and any default conversion price.
- Creditor protections: security and collateral, lien priority, guarantees, covenants, events of default, cure periods, acceleration rights, and cross-default provisions.
- Other equity-linked or transaction rights: warrants and their exercise-price adjustments, plus change-of-control, refinancing, redemption, or repurchase provisions.
Terms can vary materially between issuers. SEC-filed examples include arrangements with scheduled amortization, an original issue discount, one-time interest, or a conversion discount that may apply after default, as well as notes requiring cash payment at maturity or potentially cash settlement in other circumstances. Treat these as examples of clauses to look for, not as terms that apply to the company you are evaluating.
How much dilution could convertible notes cause?
Estimate conversion shares from the contract’s formula under several plausible future share or financing prices. If accrued interest can convert, include it. Aggregate all outstanding notes and other potentially issuable shares, including warrants and options, and compare ownership on the same fully diluted basis before and after conversion.
A discount, valuation cap, reset, or default-price provision can make the eventual share count sensitive to financing terms or market conditions. Consequently, an initial conversion price is not enough to estimate dilution when the contract provides for another price in specified circumstances. SEC-filed investor offering disclosure explains that a discount or cap may give noteholders more shares for their investment and draws attention to the aggregate amount of notes issued and potentially to be issued.
Free tools Windows power users keep installed
One-click scans. No signup required.
Keep the share calculation separate from the cash calculation. Model scheduled payments, principal at maturity, and possible cash settlement even if conversion is also possible. For each scenario, identify which party can elect conversion or cash settlement and what event triggers that choice.
Can the company repay its convertible debt at maturity?
Compare each payment date and maturity date with the company’s estimated funding needs and milestone schedule. Ask whether cash on hand and credible financing sources appear sufficient for the contractual obligations. A planned financing, management expectation, or potential transaction is not a committed source of cash unless the relevant transaction is binding and available.
For the downside case, examine what happens if the next trial is delayed, misses an endpoint, or requires more funding; if the share price falls before conversion; or if financing does not occur before maturity. Identify whether the company can repay, refinance, amend, or convert the debt, and whether those choices belong to the issuer or noteholders. Check whether a breach can trigger a default, allow acceleration, or affect other obligations through cross-default provisions.
How debt terms can constrain company decisions
Debt may affect more than cash and dilution. Covenants, liens, seniority, and default rights can influence subsequent financing, asset sales, licensing arrangements, and operating flexibility. Determine which assets are pledged, where the note ranks relative to other obligations, what actions require creditor consent, and what happens after a breach. Review all amendments: the latest filing’s summary may not capture the complete set of operative terms.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How to reconcile reported expense with the cash burden
Trace reported interest expense to the note’s cash coupon, original issue discount, issuance costs, and any conversion-related accounting described in the footnotes. Then compare the contractual cash-payment schedule with the cash-flow statement. Issuance discounts and costs may be amortized into reported interest expense, so accounting expense and cash paid in a period need not match.
Rank #4
A reported loss can include non-cash expense, while a modest reported interest amount does not remove the risk of principal repayment or dilution. Accounting classification depends on the instrument’s provisions and applicable standards; the treatment disclosed for one issuer should not be assumed for another.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to compare two biotech companies or convertible notes
Make comparisons using the same reporting dates, assumptions, and fully diluted share-count basis. Keep development risk and debt risk visible as separate but connected dimensions:
| Comparison area | What to compare |
|---|---|
| Development and milestones | Stage and concentration of lead programs; quality and timing of the next clinical or regulatory milestones; and capital expected to be needed to reach them. |
| Cash and financing | Runway relative to milestone costs; committed versus prospective financing; and sensitivity to trial, manufacturing, or financing delays. |
| Effective debt proceeds and burden | Cash proceeds after discounts and fees; total repayment obligations; payment schedule; and maturity relative to estimated runway. |
| Conversion and dilution | Conversion formula, potential share-count sensitivity, settlement choices, and associated warrants or other potentially issuable securities. |
| Creditor rights | Cash-settlement exposure, collateral and lien priority, covenants, default and acceleration rights, and restrictions on company actions. |
Use figures only with the issuer, period, filing, and relevant assumptions identified. The SEC filings reviewed provide company-specific disclosures, not a representative sector-wide average for convertible-debt prevalence, dilution, or runway. Do not turn one company’s terms or estimates into an industry benchmark.
Quick Recap
A practical filing-based assessment sequence
- Identify the issuer and security. Confirm the legal issuer, security class, latest filing date, and debt documents that govern the instrument.
- Map programs and milestones. Record development stage, next steps, timing, dependencies, expected capital needs, and the stated consequences of delay or failure.
- Reconstruct available cash. Use the latest balance sheet and cash-flow statement, distinguish unavailable balances, and account for operating needs, trial commitments, and debt service.
- Extract contract terms. Capture proceeds, payment schedule, maturity, conversion formula, settlement options, collateral, covenants, default remedies, and amendments.
- Model linked scenarios. Estimate runway, payments, and potential shares under base and adverse assumptions, using the contract’s actual formula and including other potentially issuable securities.
- Check the accounting and update date. Reconcile interest expense with cash terms and note disclosures, then refresh the analysis after material filings, trial events, financings, or contract amendments.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
